Artivion Inc
Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers On-X prosthetic aortic and mitral heart valves; On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters; Chord-X ePTFE sutures; pyrolytic carbon coating services; E-vita Open NEO, a hybrid stent graft; Arcevo, an LSA hybrid stent graft system; AMDS hybrid… Read more
Artivion Inc (AORT) - Net Assets
Latest net assets as of December 2025: $448.23 Million USD
Based on the latest financial reports, Artivion Inc (AORT) has net assets worth $448.23 Million USD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($884.80 Million) and total liabilities ($436.56 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $448.23 Million |
| % of Total Assets | 50.66% |
| Annual Growth Rate | 13.21% |
| 5-Year Change | 49.05% |
| 10-Year Change | 114.48% |
| Growth Volatility | 37.5 |
Artivion Inc - Net Assets Trend (1991–2025)
This chart illustrates how Artivion Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Artivion Inc (1991–2025)
The table below shows the annual net assets of Artivion Inc from 1991 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $448.23 Million | +62.29% |
| 2024-12-31 | $276.20 Million | -1.98% |
| 2023-12-31 | $281.78 Million | -0.90% |
| 2022-12-31 | $284.33 Million | -5.45% |
| 2021-12-31 | $300.73 Million | -8.51% |
| 2020-12-31 | $328.71 Million | +15.06% |
| 2019-12-31 | $285.70 Million | +3.86% |
| 2018-12-31 | $275.07 Million | -1.42% |
| 2017-12-31 | $279.04 Million | +33.52% |
| 2016-12-31 | $208.98 Million | +34.61% |
| 2015-12-31 | $155.25 Million | +4.42% |
| 2014-12-31 | $148.69 Million | +2.72% |
| 2013-12-31 | $144.75 Million | +12.98% |
| 2012-12-31 | $128.11 Million | +5.41% |
| 2011-12-31 | $121.54 Million | +6.67% |
| 2010-12-31 | $113.94 Million | +3.17% |
| 2009-12-31 | $110.45 Million | +11.20% |
| 2008-12-31 | $99.33 Million | +58.60% |
| 2007-12-31 | $62.63 Million | +20.23% |
| 2006-12-31 | $52.09 Million | +2.90% |
| 2005-12-31 | $50.62 Million | +1.94% |
| 2004-12-31 | $49.66 Million | +2.73% |
| 2003-12-31 | $48.34 Million | -39.43% |
| 2002-12-31 | $79.80 Million | -21.33% |
| 2001-12-31 | $101.44 Million | +13.47% |
| 2000-12-31 | $89.39 Million | +11.43% |
| 1999-12-31 | $80.23 Million | -0.22% |
| 1998-12-31 | $80.40 Million | +166.23% |
| 1997-12-31 | $30.20 Million | +21.29% |
| 1996-12-31 | $24.90 Million | +21.46% |
| 1995-12-31 | $20.50 Million | +14.53% |
| 1994-12-31 | $17.90 Million | +7.83% |
| 1993-12-31 | $16.60 Million | +127.40% |
| 1992-12-31 | $7.30 Million | +10.61% |
| 1991-12-31 | $6.60 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Artivion Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 5079800000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $493.00K | 0.11% |
| Other Comprehensive Income | $-2.72 Million | -0.61% |
| Other Components | $501.96 Million | 111.99% |
| Total Equity | $448.23 Million | 100.00% |
Artivion Inc Competitors by Market Cap
The table below lists competitors of Artivion Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Recursion Pharmaceuticals Inc
NASDAQ:RXRX
|
$1.71 Billion |
|
UNIQA Insurance Group AG
VI:UQA
|
$1.71 Billion |
|
Kemper Corporation
NYSE:KMPR
|
$1.71 Billion |
|
BigBearai Holdings Inc
NYSE:BBAI
|
$1.71 Billion |
|
JTC PLC
PINK:JTCPF
|
$1.71 Billion |
|
Eastern Air Logistics Co Ltd
SHG:601156
|
$1.71 Billion |
|
Tangshan Port Group Co Ltd
SHG:601000
|
$1.71 Billion |
|
Alten SA
PA:ATE
|
$1.71 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Artivion Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 276,200,000 to 448,232,000, a change of 172,032,000 (62.3%).
- Net income of 9,768,000 contributed positively to equity growth.
- Other comprehensive income increased equity by 22,208,000.
- Other factors increased equity by 140,056,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $9.77 Million | +2.18% |
| Other Comprehensive Income | $22.21 Million | +4.95% |
| Other Changes | $140.06 Million | +31.25% |
| Total Change | $- | 62.29% |
Book Value vs Market Value Analysis
This analysis compares Artivion Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.94x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 49.58x to 3.94x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1991-12-31 | $0.75 | $37.40 | x |
| 1992-12-31 | $0.73 | $37.40 | x |
| 1993-12-31 | $1.11 | $37.40 | x |
| 1994-12-31 | $1.24 | $37.40 | x |
| 1995-12-31 | $1.41 | $37.40 | x |
| 1996-12-31 | $1.68 | $37.40 | x |
| 1997-12-31 | $2.03 | $37.40 | x |
| 1998-12-31 | $4.37 | $37.40 | x |
| 1999-12-31 | $4.27 | $37.40 | x |
| 2000-12-31 | $4.65 | $37.40 | x |
| 2001-12-31 | $5.16 | $37.40 | x |
| 2002-12-31 | $4.11 | $37.40 | x |
| 2003-12-31 | $2.45 | $37.40 | x |
| 2004-12-31 | $2.16 | $37.40 | x |
| 2005-12-31 | $2.11 | $37.40 | x |
| 2006-12-31 | $2.10 | $37.40 | x |
| 2007-12-31 | $2.32 | $37.40 | x |
| 2008-12-31 | $3.50 | $37.40 | x |
| 2009-12-31 | $3.90 | $37.40 | x |
| 2010-12-31 | $4.03 | $37.40 | x |
| 2011-12-31 | $4.38 | $37.40 | x |
| 2012-12-31 | $4.67 | $37.40 | x |
| 2013-12-31 | $5.23 | $37.40 | x |
| 2014-12-31 | $5.25 | $37.40 | x |
| 2015-12-31 | $5.44 | $37.40 | x |
| 2016-12-31 | $6.37 | $37.40 | x |
| 2017-12-31 | $8.17 | $37.40 | x |
| 2018-12-31 | $7.55 | $37.40 | x |
| 2019-12-31 | $7.55 | $37.40 | x |
| 2020-12-31 | $8.68 | $37.40 | x |
| 2021-12-31 | $7.71 | $37.40 | x |
| 2022-12-31 | $7.10 | $37.40 | x |
| 2023-12-31 | $6.92 | $37.40 | x |
| 2024-12-31 | $6.63 | $37.40 | x |
| 2025-12-31 | $9.50 | $37.40 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Artivion Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 2.18%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 2.21%
- • Asset Turnover: 0.50x
- • Equity Multiplier: 1.97x
- Recent ROE (2.18%) is above the historical average (-0.91%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1991 | -10.61% | -4.58% | 1.40x | 1.65x | $-1.36 Million |
| 1992 | 9.59% | 3.57% | 1.58x | 1.70x | $-30.00K |
| 1993 | 3.61% | 2.83% | 1.05x | 1.21x | $-1.06 Million |
| 1994 | 7.26% | 5.51% | 1.10x | 1.20x | $-490.00K |
| 1995 | 10.73% | 7.59% | 1.23x | 1.15x | $150.00K |
| 1996 | 15.66% | 10.54% | 1.06x | 1.41x | $1.41 Million |
| 1997 | 15.56% | 9.23% | 0.95x | 1.78x | $1.68 Million |
| 1998 | 8.08% | 10.71% | 0.62x | 1.22x | $-1.54 Million |
| 1999 | 5.55% | 6.67% | 0.71x | 1.17x | $-3.57 Million |
| 2000 | 8.74% | 10.14% | 0.69x | 1.25x | $-1.12 Million |
| 2001 | 9.04% | 10.45% | 0.68x | 1.27x | $-977.90K |
| 2002 | -34.79% | -35.68% | 0.73x | 1.33x | $-35.74 Million |
| 2003 | -66.81% | -54.25% | 0.79x | 1.55x | $-37.13 Million |
| 2004 | -37.75% | -30.05% | 0.85x | 1.48x | $-23.71 Million |
| 2005 | -38.59% | -28.20% | 0.90x | 1.52x | $-24.60 Million |
| 2006 | 0.70% | 0.45% | 1.02x | 1.53x | $-4.84 Million |
| 2007 | 11.50% | 7.60% | 1.02x | 1.48x | $938.30K |
| 2008 | 33.13% | 31.32% | 0.83x | 1.27x | $22.98 Million |
| 2009 | 7.86% | 7.77% | 0.83x | 1.21x | $-2.37 Million |
| 2010 | 3.46% | 3.38% | 0.85x | 1.21x | $-7.45 Million |
| 2011 | 6.06% | 6.16% | 0.81x | 1.22x | $-4.78 Million |
| 2012 | 6.20% | 6.03% | 0.84x | 1.23x | $-4.87 Million |
| 2013 | 11.17% | 11.49% | 0.81x | 1.21x | $1.70 Million |
| 2014 | 4.92% | 5.06% | 0.82x | 1.18x | $-7.55 Million |
| 2015 | 2.58% | 2.75% | 0.81x | 1.17x | $-11.52 Million |
| 2016 | 5.16% | 5.98% | 0.57x | 1.51x | $-10.12 Million |
| 2017 | 1.33% | 1.95% | 0.32x | 2.12x | $-24.20 Million |
| 2018 | -1.38% | -1.45% | 0.46x | 2.08x | $-31.31 Million |
| 2019 | 0.60% | 0.62% | 0.46x | 2.12x | $-26.85 Million |
| 2020 | -5.07% | -6.59% | 0.32x | 2.40x | $-49.55 Million |
| 2021 | -4.93% | -4.96% | 0.38x | 2.64x | $-44.91 Million |
| 2022 | -6.75% | -6.12% | 0.41x | 2.68x | $-47.62 Million |
| 2023 | -10.89% | -8.67% | 0.45x | 2.81x | $-58.87 Million |
| 2024 | -4.84% | -3.44% | 0.49x | 2.86x | $-40.98 Million |
| 2025 | 2.18% | 2.21% | 0.50x | 1.97x | $-35.06 Million |
Industry Comparison
This section compares Artivion Inc's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $539,803,485
- Average return on equity (ROE) among peers: -52.41%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Artivion Inc (AORT) | $448.23 Million | -10.61% | 0.97x | $1.71 Billion |
| Advanced Biomedical Technologies Inc (ABMT) | $-7.40 Million | 0.00% | 0.00x | $14.18K |
| Abbott Laboratories (ABT) | $3.67 Billion | 38.07% | 1.09x | $190.05 Billion |
| Acarix AB (publ) (ACIXF) | $1.44 Million | -102.09% | 0.28x | $26.42 Million |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-13.54K | 0.00% | 0.00x | $4.05 Million |
| Adm Tronics Unltd (ADMT) | $2.76 Million | -21.69% | 0.89x | $3.17 Million |
| Aethlon Medical Inc (AEMD) | $9.28 Million | -68.70% | 0.12x | $2.76 Million |
| Acutus Medical Inc (AFIB) | $126.58 Million | -80.56% | 0.52x | $732.88K |
| Adapthealth Corp (AHCO) | $1.58 Billion | 5.73% | 1.84x | $911.62 Million |
| Allied Healthcare Products Inc. (AHPIQ) | $11.89 Million | -17.74% | 0.30x | $726.24 |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $456.18K | -277.12% | 2.12x | $10.62 Million |